Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in ChinaResearch in context

Summary: Background: Urachal carcinoma (UrC) constitutes a rare and biologically distinct adenocarcinoma for which no standardised therapeutic regimen currently exists. We aimed to evaluate the efficacy and safety of combined therapy with camrelizumab, a humanised monoclonal anti programmed death-1...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mengyang Ju, Wenfeng Li, Linjun Hu, Xiongjun Ye, Wangjun Yan, Sheng Zhang
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-06-01
Col·lecció:	EClinicalMedicine
Matèries:	Urachal cancer Camrelizumab Apatinib PD-1 inhibitor VEGFR inhibitor Clinical trial
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537026002269
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!